Author
@FierceBiotech FierceBiotech
Biotech trade-press outlet breaking trial, deal, and FDA news with clinical context
Report original biotech/pharma industry news — clinical read
trader score
-0.09
hit rate
45%
mean α
-0.06%
signals 14d
27
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 45% hit rate, -0.06% mean alpha, trader score -0.09. Their last-14d mentions, direction-adjusted, have moved +1.2% since posting (mean over 15 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-01 | IPN.PA | @FierceBiotech | -0.10 | Ipsen scoops up second biotech in three days to add clinical-stage candidates. | · | tweet ↗ |
| 2026-06-30 | · | @FierceBiotech | · | FDA gene therapy regulator steps down from leadership role. | · | tweet ↗ |
| 2026-06-30 | PRAX | @FierceBiotech | -0.30 | Praxis faces FDA decision delay, a negative regulatory timing event. | -4.9% | tweet ↗ |
| 2026-06-30 | VTGN | @FierceBiotech | -0.60 | Vistagen drug candidate flunked another phase 3 trial despite post hoc analysis. | · | tweet ↗ |
| 2026-06-29 | · | @FierceBiotech | · | BioCryst ends internal discovery programs and closes facility for cost-saving pivot | · | tweet ↗ |
| 2026-06-29 | · | @FierceBiotech | · | Scancell bids to buy Nasdaq-listed Neuphoria | · | tweet ↗ |
| 2026-06-29 | · | @FierceBiotech | · | AstraZeneca unveils phase 3 data behind $5B forecast for Strensiq successor | · | tweet ↗ |
| 2026-06-29 | · | @FierceBiotech | · | Talawar going to Nasdaq via SPAC deal | · | tweet ↗ |
| 2026-06-29 | NVS | @FierceBiotech | +0.20 | Evommune phase 2b trial flop ends challenge to Novartis in hives | +1.5% | tweet ↗ |
| 2026-06-29 | · | @FierceBiotech | · | Ipsen paying $450M upfront to buy Kartos Therapeutics | · | tweet ↗ |
| 2026-06-25 | IONS | @FierceBiotech | +0.35 | Ionis gets $30M from Recordati for ex-US rights to rare disease prospect. | · | tweet ↗ |
| 2026-06-25 | OTSKY | @FierceBiotech | +0.50 | Otsuka phase 3b ADHD prospect hit primary endpoint before possible US launch. | · | tweet ↗ |
| 2026-06-24 | NVS | @FierceBiotech | +0.10 | Novartis pays $105mn upfront in cancer drug discovery deal worth up to $1.9bn. | +4.4% | tweet ↗ |
| 2026-06-24 | LLY | @FierceBiotech | +0.15 | Eli Lilly reunites with Abbisko in $1.9B multi-target R&D pact. | +8.7% | tweet ↗ |
| 2026-06-23 | LLY | @FierceBiotech | +0.05 | Sangamo to sell substantially all assets in bankruptcy, with Lilly and Astellas lined as buyers. | +9.6% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.